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Abstract 
Background: Triple negative breast cancer represents a significant treatment challenge due to 
its inherent aggressiveness and lack of targetable receptors, consequently generating a need for 
novel treatment approaches. Autophagy, a self-degradative pathway that provides metabolic 
substrates and recycles damaged proteins and organelles, has been implicated in supporting 
cancer survival, progression towards metastasis, and chemotherapeutic resistance. Autophagy 
inhibition has exhibited weak effects on cancer by itself but provides a quality therapeutic target 
in combination with agents that exploit autophagy deficient cell vulnerabilities, classically 
through nutrient or chemotherapeutic stress. However, the success of autophagy inhibition in 
combination therapies has been shown to be highly tumor type, stage, and oncogene dependent, 
thus making researching the effect of autophagy and exogenous stress on Triple negative breast 
cancer an important avenue for continuing autophagy and cancer research.   
 
Methods: In order to characterize autophagy deficient metastatic TNBC in vitro, ATG5, an 
essential autophagy protein, was knocked out using a CRISPR/Cas 9 construct in both a 
mesenchymal mouse derived TNBC cell dubbed the M-Wnt and in a metastatic line developed 
from M-Wnt lung metastases, called the metM-Wntlung. Experiments using both Wild-Type and 
autophagy deficient lines assayed relative growth, energy generation potential, EMT phenotype, 
and response to stress in the form of chemotherapeutics and nutrient starvation.  
 
Results: Relative to their autophagy competent counterparts, Atg5-/- cells showed decreased 
growth and significantly altered metabolism, displaying high basal energetics but reduced 
maximum energy production. Autophagy inhibition alone also resulted in downregulation of 
EMT regulators Twist, Snail, and Slug, and morphologically exhibited signs of an EMT 
reversion. Growth and metabolic effects were not observed across all exogenous stressors; only 
serum starvation and doxorubicin treatment appeared to act synergistically with autophagy 
inhibition to reduce cancer growth. Reactive oxygen species induced by doxorubicin and an 
inability to balance redox stress via an antioxidant response (NRF2) may underlie synergistic 
chemotherapy effects.  
 
Conclusions: These findings suggest that autophagy inhibition induces broad cellular changes, 
including metabolic alterations that strengthen specific nutrient and chemotherapeutic treatments. 
Further investigation of this model in vivo and identification of a molecular target to maximize 
autophagy inhibition effects have potential to lead to practical, effective adjuvant or neoadjuvant 
combination therapies. 
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Introduction 
Breast Cancer Prevalence and Mortality 
Breast cancer is the most prevalent cancer and second leading cancer-related cause of 
death in women, amassing an estimated 252,710 new diagnoses and 40,610 deaths in 20171. It 
makes up to 30% of all female cancer diagnoses, and while 5 year survival rates for Stage 0 or 
stage 1 breast cancers are nearing 100%, treatment of advanced breast cancer has not been as 
successful1,2. Widespread mammography screening and the advent of molecular diagnostics have 
improved overall breast cancer death rates at a mark of 1.9% every year from 2004 to 2013, but 
progress on certain molecular subtypes has been slow2. Breast cancers can be broken down into 
multiple subtypes by DNA and gene expression, with the major subtypes being luminal A, 
luminal B, HER-2 enriched, and Triple Negative3. Each subtype confers a different prognosis 
and different treatment options, and Triple negative breast cancer (TNBC) represents a 
significant challenge in current breast cancer treatment. 
Triple negative breast cancer  
Triple negative breast cancer makes up 12% of total breast cancer cases and is classified 
by the lack of estrogen receptors (ER-), progesterone receptors (PR-), and HER2/neu expression 
(HER2-)4. Accordingly, TNBC also lacks the highly effective hormonal and monoclonal 
antibody therapies that have been used to target breast cancers expressing these receptors. 
Compared to the other subtypes of breast cancer, patients with Triple negative breast cancer were 
more likely to receive chemotherapy, have a shorter time to recurrence, display more aggressive 
tumors, and exhibit worse overall survival5–7. Triple negative breast cancer also embodies a 
public health concern in the form of a racial health disparity, as black women are twice as likely 
white women to be diagnosed with TNBC and had twice the 7 year risk of death from Stage 1 
TNBC as white women4,8,9. Surgery and chemotherapy have been the traditional treatment 
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approaches for TNBC, but as oncology and molecular biology have advanced, the field is 
looking to replace these highly damaging strategies with targeted, low toxicity treatments.  
Genetically, Triple negative breast cancer is more problematic than other breast cancers. 
TNBC is highly heterogeneous, and unlike the other subtypes with common oncogene drivers, 
the only genes mutated in 10% or more of TNBCs are TP53 and PIK3CA10. Thus, there are few 
actionable pathways that can be targeted across all TNBCs, although combination therapy 
targeting PI3K/mTOR and RAS/RAF/MEK has shown promise in current clinical trials5,7. 
TNBC is also the most likely subset of breast cancer to be claudin-low, a recently defined 
molecular subtype that identifies cancers as showing low expression of the claudin genes 
involved in epithelial junctions and is associated with poorer distant metastasis-free survival at 5 
years3,11. Most importantly, claudin-low breast cancers are known to be enriched in tumor 
initiating cells and show stem cell phenotypes, the subpopulations implicated in tumorigenesis, 
tumor progression, and chemotherapeutic resistance3,12,13. Future TNBC therapies should have a 
role in reducing metastasis of these highly aggressive tumors.   
Additionally, traditional research on breast cancer and triple negative breast cancer has 
centered on RAS driven cancers, and the Wnt pathway represents a missed opportunity. Wnt 
signaling in cancer is well described regulator of a wide variety of processes including 
differentiation, proliferation, and cell motility and invasion, but is generally understood to drive 
highly proliferative, aggressive and phenotypes across all cancers when dysregulated14. Aberrant 
Wnt signaling is common in TNBC and associated with poor clinical outcomes within TNBC; 
patients with abnormal Wnt/β-catenin signaling are more likely to develop lung and brain 
metastases than with other genetic drivers11,14.  
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Thus, there is a strong need for new approaches and novel therapies to treat Triple 
negative breast cancer in general, and especially a demand to explore avenues for treating highly 
metastatic and tumor cell enriched Wnt-driven and claudin-low cancers.  
Autophagy and Cancer 
  The relatively recent discovery of autophagy provides a novel, targetable approach for 
TNBC treatment. Autophagy can be generally classified into three groups: macroautophagy, 
microautophagy, and chaperone-mediated autophagy (CMA)15,16. Both microautophagy and 
CMA have important cellular roles, but macroautophagy (hereafter referred to as autophagy) is 
the major catabolic pathway implicated in multiple pathogeneses, particularly in cancer17. In the 
process of autophagy, cellular contents are sequestered in a double membrane vesicle and then 
fused to lysosomes for degradation. Its canonical effect is two-fold: autophagy-mediated 
degradation provides macromolecules under nutrient stress to fuel ATP production and 
biosynthesis as well as recycling damaged proteins and organelles as a stress response. 
Autophagy is induced by hypoxia, ER stress, nutrient starvation, especially amino acid 
deprivation, and provides a way for all cells, and especially cancer cells, to respond to 
intracellular and extracellular change18,19. The full mechanisms surrounding autophagy 
regulation and its effects on cancer cells are incomplete, but the phosphatidylinositol 3-
kinase/mammalian target of rapamycin (PI3K/mTOR) pathway is recognized as the primary 
regulator of autophagy; mTOR integrates nutrient, growth factor, and stress signals and mTOR 
activation inhibits autophagy in order to promote growth20. 
 Autophagy’s role in cancer is highly complex and dependent on cancer type, tumor stage, 
and oncogene, making research on autophagy in less-well studied cancer phenotypes a 
necessity17,20,21. However, autophagy is generally considered to suppress early stages of cancer 
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but promote survival and progression towards metastasis in solid tumors and later stage 
cancer17,23. Autophagy activation reduces cellular stress and DNA damage, therefore suppressing 
tumorigenesis and reducing genomic instability24,25. These effects led to initial understandings of 
autophagy as a tumor suppressor, but it seems that cancer preventative effects are most salient in 
tumor formation, while the pro-survival effects of autophagy dominate once a solid tumor is 
established26,27. Autophagy promotes survival of established tumors in hypoxic, nutrient-poor, or 
otherwise stressful environments, and is known to support the survival of dormant tumor cells, 
disseminating tumor cells in circulation, and stem-like subpopulations of tumor cells responsible 
for invasion and chemotherapy resistance24,28,29.  
 Perhaps most importantly, autophagy has been implicated as an important player in 
cancer progression towards metastasis, the primary cause of cancer related death30,31. Evidence 
indicates direct regulation of EMT, tumor cell migration, and invasion by autophagy, and in 
certain “autophagy-addicted” cancers, like KRAS mutated lines, autophagy has been shown to be 
necessary for metastasis21,32,33. Considering that fewer than 30% of women with breast cancer 
metastases survive 5 years post-diagnosis and nearly all women with metastatic TNBC will die 
of cancer related complications, targeting autophagy in order to impact metastasis could prove 
critical to improving breast cancer mortality in the future5. 
Autophagy Inhibition Combination Therapy 
 As autophagy plays a crucial role in a variety of cellular processes, its inhibition provides 
multiple metabolic vulnerabilities that can be exploited in cancer therapy. In much of the seminal 
autophagy research, one of the 30 core autophagy proteins, typically ATG5, ATG7, or ATG12, 
is genetically knocked out or silenced in mice after-birth, as nearly all ATG-/- genetically 
engineered mouse models result in neonatal death34. Inhibition is pharmacologically achieved 
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with hydroxychloroquine or 3-methyladenine most commonly, but their inhibition is weak 
compared to genetic inhibition35,36. However, hopes of potent novel inhibitors have sustained the 
push towards using autophagy inhibition in combination to sensitize cancer before or during 
chemotherapy treatment. Specifically, combining autophagy inhibition with nutrient and 
chemotherapeutic stressors hopes to take advantage of the lack of autophagy’s two major 
functions: provision of metabolic fuel under stress and responding to cell stress by clearing 
intracellular damage.  
 Altering nutrient intake was indicated as a novel therapy for a host of diseases before 
cancer was considered, but combining nutrient intake modulation, especially calorie restriction, 
and autophagy inhibition is yielding positive results in pre-clinical studies. Calorie restriction 
(CR) has been well demonstrated to be cancer preventative, but recent research has turned 
towards using CR to sensitize cancer to radiation and chemotherapies37–39. In vitro work has 
shown sensitization of autophagy deficient colon cancer cells to glucose restriction40,41. More 
significantly, in a in vivo study by Lashinger et al., a combination of calorie restriction and 
autophagy inhibition resulted in the lowest tumor burden among all given populations26. 
However, there is still gap in knowledge to be filled, as none of the studies were performed on 
Triple negative breast cancer, and questions remain as to whether autophagy deficient cancers 
are vulnerable to CR mimetics such as Metformin or IGF1R inhibitors  
 Autophagy’s role in chemotherapeutic resistance is unfortunately as context dependent as 
its role in cancer, but multiple clinical trials are underway to determine the contexts in which 
combination chemotherapy and autophagy inhibition are successful22,35. Autophagy has been 
implicated as a mechanism for chemotherapy resistance, as cells can upregulate autophagy to 
balance redox stress and suppress intracellular DNA and organelle damage42. Additionally, 
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chemotherapy and radiation therapy both are known to induce autophagy upregulation, but this 
doesn’t necessarily indicate a dependence on autophagy42. On the other hand, excessive 
autophagy induced by chemotherapeutics has been associated with cell death and autophagy 
mediated cell death may be a mechanism through which some chemotherapeutic agents 
act22,43.Thus, dependent on the contexts, autophagy inhibition and chemotherapeutic combination 
therapy can increase killing or protect cells 22,42. There is no clear answer as to the success of 
combination chemotherapy autophagy inhibition, but the 12 phase I and II clinical trials and 
bounds of preclinical studies should illuminate its potential. However, none of the clinical trials 
and few preclinical studies assess combination therapy effectiveness in TNBC, much less in 
highly aggressive Wnt driven, claudin-low TNBC. 
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Goal and Hypotheses 
 The primary goal of this study was to better understand the effects of autophagy 
inhibition with and without exogenous stressors in Wnt driven claudin-low Triple negative breast 
cancer. The study was accomplished through three specific aims, the first aim being to determine 
the effects of autophagy inhibition alone in the M-Wnt and metM-Wntlung, specifically in the 
areas of growth, metabolic ability, and invasive phenotype. Our corresponding hypothesis is that 
autophagy inhibition alone in high nutrient contexts will cause moderate decreases in growth and 
oxidative phosphorylation, but few other effects. The second specific aim is to assay cellular 
changes of autophagy deficient cells in response to exogenous stress in the form of nutrient 
modulation or chemotherapeutics. As found in a previous in vivo study within the lab, we expect 
a combination of autophagy inhibition and in vitro calorie restriction mimic to result in the 
lowest amount of growth relative to autophagy competent and high nutrient conditions26. 
Additionally, we hypothesize that autophagy inhibition will sensitize cancer to all types of 
nutrient stress but will not sensitize cancer to all chemotherapeutics, as prior work has shown 
autophagy inhibition effectiveness with chemotherapeutics to be highly context dependent21,42,44. 
The third specific aim is to elucidate potential mechanisms underlying interactions between 
autophagy inhibition and exogenous stress. Our hypothesis is that the accumulation of damaged 
organelles, especially mitochondria, and inability to provide endogenous metabolic fuel place 
autophagy deficient cancer cells in a state of reduced metabolic plasticity18. Adding further stress 
through restriction of nutrients or the addition of chemotherapeutic agents results in excessive, 
unbalanced ROS and mitochondrial damage induced apoptosis. 
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Methods 
Generation of Wild-Type and Autophagy Deficient TNBC Cell Lines 
 Previously described fully in Dunlap et al. 201213 and O’Flanagan et al. 2017, the M-Wnt 
cell line was developed from spontaneous mammary tumors in MMTV-Wnt-1 transgenic mice45. 
The M-Wnt line has mesenchymal morphology, is strongly mammosphere forming, and shows 
high migratory and invasive ability13. The metM-Wntlung cell line was derived through harvesting 
of lung metastases in severe combined immunodeficient mice after serial transplantation of M-
Wnt cells in 5 generations of mice. metM-Wntlung cells were analyzed and found to display 
multiple markers and behaviors of metastatic and TIC enriched populations45.   
Autophagy deficient cell lines of both the M-Wnt and metM-Wntlung lines were generated 
via a CRISPR/Cas9 lentiviral vector (Sigma-Aldrich) containing both Puromycin resistance and 
GFP components. This lentivirus was used to transduce and knockout ATG5, a protein required 
for autophagy, in both the M-Wnt and metM-Wntlung cell lines44. Post-transduction, cells were 
selected by culturing in media with Puromycin, and clonal populations were generated from 
single cells. Clones with strong knockout were screened by GFP expression and ultimately 
selected by Western Blot (Figure 1A). The populations chosen as the M-Wnt and metM-Wntlung 
ATG5-/- lines expressed little to no ATG5 protein and high LC3B-1:LC3B-II ratio, a marker of 
autophagy induction without formation of autophagosomes16.  
Growth Assays 
Long Term Survival 
Colony formation assays were used to measure long term survival and ability to form 
colonies. Cells were seeded into 6 well plates at 1 × 103 cells/well. Plates were incubated and 
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grown for 14 days with complete, 1% FBS, 1mM, or FA- media. At day 7 for all experiments, 
media was replaced with fresh media of the respective treatment. At day 14, cells were fixed in 1 
mL of 100% methanol for 10 minutes. Methanol was aspirated and replaced with 1 mL 0.5% 
Crystal Violet in 50% methanol for 30 minutes. Plates were then washed with water and stained 
colonies were counted by hand.  
Short Term Survival & Dose Response Curve 
MTT survival assays were used to measure short term survival and dose response to 
chemotherapeutics. Cells were seeded at 5 × 103 cells/well in a 96 well plate, incubated for 24 
hours, then media was replaced with treatment media (1% FBS, 1mM Glucose, FA-, 
+Chemotherapeutic) or complete media. At 48 hours, cell media was replaced with 100 µL of 
0.5 mg/mL of MTT reagent in complete media for 1 hour, covered with aluminum foil. MTT 
media was then aspirated, 100 µL of DMSO was added, and plates were placed on a microplate 
shaker at 1,000 RPM for 5 minutes. Using the Cytation 3 Cell Imaging Reader (BioTek) to 
obtain measurements, absorbance at 690 nm subtracted from absorbance at 595 nm was used as 
relative measure of survival. All relative survival measurements were normalized to a non-
treated control population.  
Metabolic Flux Analysis 
Cellular bioenergetics were collected using the Seahorse XFe96 Analyzer (Agilent 
Technologies) with a Mito Stress Test Kit. Cells were seeded at 15 × 103 cells/well in a 96 Well 
Seahorse XF Microplate for 24 hours with complete media, then media was switched to 
treatment media (1% FBS, 1mM Glucose, FA-). Following 48 hours of treatment, cells were 
incubated for 1 h at 37 °C in a CO2-free atmosphere, then media was replaced with 1 mM 
pyruvate, 2 mM glutamine, and 10 mM glucose supplemented Seahorse XF Base Media at pH 
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7.4. OCR and ECAR were measured following administration of oligomycin (1 µM), carbonyl 
cyanide-4-(trifluormethoxy) phenylhydrazone (FCCP) (1µM), and antimycin A (3µM)/rotenone 
(3 µM). Results were normalized to μg protein using a BCA protein assay (Thermo Fisher). 
EMT Transcription Factor and Biomarker qPCR 
MetM-Wntlung cells were seeded into 6 wells at 500 × 103 cells/well for qPCR with 
complete RPMI media. After 48 hours, cells were harvested with Trizol reagent (Sigma Aldrich) 
into 1.5-mL microcentrifuge tubes for storage at -80° C, then RNA was isolated and cDNA 
synthesized. EMT transcription factors and biomarkers were measured by qPCR using 
TaqManTM Gene Expression Assays. Data was collected on a ViiA7 (Applied Biosystems). Gene 
expression data were normalized to β-actin. 
Mitochondria and Reactive Oxygen Species Flow Cytometry 
For all experiments, cells were seeded at 350 × 103 cells/well in a 6 well plate and grown 
for 24 hours, at which media was replaced with either complete media or a treatment media as 
described earlier. Samples were then incubated for 48 hours, after which cells washed with PBS 
and fluorophore solution was added. All sample data contained at least 50,000 ungated events, 
and was collected using an Accuri C6 Flow Cytometer (BD Biosciences) and analyzed with 
FlowJo software (BD Biosciences).  
Mitochondrial Membrane Polarization 
MitoTracker Red CMXRos (Invitrogen) in complete media was added at 100nm for 30 
minutes. Cells were washed with PBS, collected via 0.05% trypsin, and then resuspended in 
PBS. Relative fluorescence intensity at detector FL-2 was used as a measure of mitochondrial 
polarization. FCCP was added at 100uM for 30 minutes as a positive control46.  
General ROS 
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General reactive oxygen species were measured via the Cellular Reactive Oxygen 
Species Detection Assay Kit, Deep Red Fluorescence (Abcam). 1 µL of ROS Deep Red stock 
solution per mL of complete media was placed on cells for 30 minutes. Media was aspirated, 
cells were washed with PBS, collected by 0.5 M EDTA, washed again and then resuspended in 
PBS. Fluorescence intensity at detector FL-4 was used a measure of general ROS species in the 
cell. Menadione in complete media at 30 µM for 30 minutes was used as a positive control47. 
Quantifying Mitochondrial Superoxide 
A solution of 3 µM MitoSOX Red Mitochonrial Superoxide Indicator (Invitrogen) in 
complete media was added to cells for 10 minutes. Media was aspirated, cells washed with 
DPBS, collected using 0.5 M EDTA and washed using DPBS with 2% FBS. Cells were fixed in 
2% paraformaldehyde for 10 minutes and then resuspended in 0.5 mL of PBS. Relative 
fluorescence intensity at detector FL-2 was used as a measurement of mitochondrial superoxide 
production. A solution of Menadione in complete media at 30 µM for 30 minutes was used as a 
positive control47. 
Western Immunoblot Analysis 
Cells were lysed in RIPA buffer. Forty micrograms of protein were loaded into a 4–15% 
stain-free gel (Biorad). Proteins were resolved and transferred to a PVDF membrane using a 
Transblot Turbo transfer unit (Biorad). Membranes were blocked with 5% bovine serum albumin 
for 1 hour before being incubated overnight at 4 °C with one of the following primary 
antibodies: rabbit ATG5, rabbit LC3B, rabbit NRF2, mouse PCNA, or mouse anti-β-Actin 
(Santa Cruz Biotechnology), followed by HRP-conjugated secondary antibodies raised against 
rabbit or mouse IgG (Sigma Aldrich). Proteins were visualized using a Chemi Doc MP system 
(Biorad).  
16 
 
Statistical Analysis 
All data was analyzed using GraphPad Prism 7 software. Differences between ATG5 
Knockouts and Wild-Type were analyzed by Student’s t-test and ANOVA using Tukey’s 
multiple comparisons test. P < 0.05 was considered statistically significant, indicated by * in 
figures.  
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Results 
Autophagy Inhibition Alone 
 Growth and Proliferation 
 CRISPR/Cas9 knockout of ATG5 is partial in the M-Wnt line and complete in metM-
Wntlung, but both populations show autophagy induction without formation of autophagosomes, 
as assayed by LC3B cleavage (Figure 1A)16,48. Cell growth is decreased in ATG5 knockouts and 
compounds over time (Figure 1B). Clonogenic assays, a proxy for long term growth, show 
significant decreases in colony formation over 14 days (Figure 1C,1D).  
 
 
 
 
 
 
 
 
Figure 1. In vitro growth effects of autophagy inhibition (A) Immunoblot analysis of ATG5 expression 
and LC3B cleavage (B) Growth curve of metM-Wntlung (C) 14-day clonogenic assay (D) Respective 
photos of clonogenic assay 
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Metabolic Ability 
 Autophagy deficient cells show significantly increased basal oxygen consumption rate 
and significantly decreased maximum oxygen consumption (Figures 2A, 2B). Furthermore, 
ATG5 knockouts do not respond to injections of electron transport chain inhibitors, unlike 
autophagy competent cells (Figure 2A). Autophagy deficient metM-Wntlung  also display a 
significantly elevated basal extracellular acidification rate, but similar maximum inducible 
extracellular acidification rates (Figures 2C, 2D) 
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Figure 2. Metabolic effects of autophagy inhibition. (A) Oxygen consumption rates in nutrient-
replete conditions, FCCP administration establishes maximum respiratory capacity. (B) Basal 
(left) and maximum (right) oxygen consumption rates of metM-Wntlung. (C) Extracellular 
acidification rate (ECAR) of metM-Wntlung (D) Basal (left) and maximum (right) ECAR of 
metM-Wntlung   
 
Morphology and EMT Biomarkers 
Wild-Type metM-Wntlung cells show mesenchymal-like or fibroblast-like morphology 
with elongated spindle cytoplasm, consistent with human claudin-low breast cancer lines (Figure 
3A). Autophagy deficient metM-Wntlung display epithelial-like morphology, growing with 
polygonal shapes in sheets (Figure 3B). Real-time PCR yielded significant downregulation of 
EMT transcriptional factors Snail, Slug, and Twist in autophagy deficient metM-Wntlung cells 
relative to Wild-Type cells (Table 1). Additionally, borderline significant changes were found in 
structural and junction proteins Vimentin, E-Cadherin, and N-Cadherin (Table 1).  
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Figure 3. Representative photomicrographs of (A) metM-Wntlung Wild-Type cells and (B) autophagy 
deficient metM-Wntlung cells  
Gene Fold Change p-value Gene Description 
Snail (SNAI1) -1.901 0.0007 
Repressor of E-Cadherin. Snail expression in 
breast cancers is associated with metastasis, 
tumorrecurrence and poor prognosis49,50 
Slug (SNAI2) -1.697 0.0431 E-Cadherin transcriptional repressor 
Twist (TWIST1) -1.418 0.0282 Upregulates N-Cadherin, has a role in promotion of metastasis and CSC maintenance51,52 
Zeb (ZEB1) -1.547 0.0712 E-Cadherin transcriptional repressor, promotes malignant progression towards metastasis53 
    
Vimentin (VIM) -1.748 0.0681 
Intermediate filament protein expressed 
ubiquitously in mesenchymal cells, associated 
with EMT progression54 
E-Cadherin 
(CDH1) 1.285 0.1624 
Epithelial cell-cell adhesion protein, 
downregulation is a biomarker for increased 
invasiveness and metastasis49 
N-Cadherin 
(CDH2) -1.219 0.0598 
Protein in neural cell-cell adhesions, a biomarker 
for mesenchymal phenotype and upregulation 
associated with endothelial invasion55 
Table 1. EMT transcription factors and biomarkers altered by ATG5 knockout.  
 
 
 
A B 
21 
 
Autophagy Inhibition in Combination with Exogenous Stress: 
Growth and Proliferation 
 48-hour growth in M-Wnt cells is reduced by 1% FBS treatment, however there is no 
compounding effect on growth with autophagy inhibition (Figure 4A, 4B). In long-term 
clonogenic assays, 1% FBS in combination with autophagy inhibition works synergistically in 
suppressing growth, forming only 14% of the colonies that autophagy competent cells in 
nutrient-replete media do (Figure 4C, 4E). Glucose restriction strongly reduces colony formation 
over 14 days but has no additive effect with autophagy inhibition (Figure 4D).  
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Figure 4. Growth effects of autophagy inhibition in combination with nutrient stress in M-Wnt (A) 48 hr 
MTT survival assay (Control is 10% FBS) (B) 48 hr MTT survival assay (Control is 25 mM glucose) (C) 
14 day clonogenic assay (D) 14 day clonogenic assay (E) Representative photographs of Figure 4C 
Metabolic Ability 
 ATG5 knockout decreases maximum oxygen consumption rate and extracellular 
acidification rate across treatments (Figures 5A, 5B). Glucose restriction in autophagy deficient 
cells significantly decreases maximum OCR but does not display a corresponding rise in ECAR, 
while 1% FBS does not have a significant effect on either measure (Figures 5A,5B) 
 
 
 
 
 
 
 
Figure 5. Metabolic effects of combined autophagy inhibition and nutrient stress in metM-Wntlung. (A) 
Maximum oxygen consumption rate. (B) Maximum extracellular acidification rate. 
Chemotherapy Response 
 Autophagy inhibition sensitizes metM-Wntlung cells to Doxorubicin at multiple 
concentrations (Figure 6A). No differential survival in MTT assays was found between Wild-
Type and ATG5 KO for Paclitaxel, Gemcitabine and calorie restriction mimetics Metformin and 
BMS-754807, an IGF1R inhibitor (Figure 6B).  
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Figure 6. Chemotherapeutic dose response curves in metM-Wntlung. (A) Doxorubicin  
(B) Paclitaxel, representative of non-significant chemotherapeutic agents 
 
Mitochondria and Reactive Oxygen Species Analysis:  
Mitochondrial Membrane Polarization 
 Staining with CMXRos reveals a lower mitochondrial membrane polarization under 
nutrient-replete conditions in autophagy deficient metM-Wntlung (Figure 7A). Doxorubicin 
treatment induces higher mitochondrial membrane polarization in Wild-Type cells, but only 
marginally in ATG knockouts (Figure 7B).  
 
 
 
 
 
 
 
 
 
Figure 7. Effects of autophagy inhibition and exogenous stress on mitochondrial membrane polarization. 
(A) Representative frequency histogram of cellular fluorescence; lower fluorescence indicates lower 
mitochondrial membrane polarization (B) Median fluorescence intensity. Doxorubicin treatment at 55 
nm. 
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General and Mitochondrial ROS 
 Autophagy deficient metM-Wntlung display lower general ROS than Wild-Type cells 
under nutrient replete conditions (Figure 8A). In Doxorubicin treatment, but not in Gemcitabine 
treatment, ATG5 knockouts have higher general reactive oxygen species than Wild-Type cells 
(Figures 8B, 8C). Autophagy deficient metM-Wntlung show lower mitochondrial ROS, primarily 
superoxide, in both nutrient replete and serum starvation conditions (Figure 8D).   
 
 
 
 
 
 
 
Figure 8. Reactive oxygen species presence in response to chemotherapeutic stress in metM-
Wntlung. (A) Frequency histogram of general ROS in nutrient-replete conditions (B) General 
ROS after 48 hr Doxorubicin treatment at 55 nm (C) General ROS after 48 hr Gemcitabine 
treatment at 30 nm (D) Mitochondrial superoxide production, median fluorescence intensity 
reported 
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Intracellular Stress Response 
 ATG5 knockout M-Wnt cells display high NRF2 induction basally whereas Wild-Type 
cells show little NRF2 protein. Additionally, autophagy deficient cells are unable to continue 
inducing NRF2 under 48 hour and 14 day folic acid deprivation, while Wild-Type cells can 
maintain NRF2 protein (Figure 9). 
 
Figure 9. Antioxidant response to folic acid deprivation. Inserted Western Blots indicate protein 
expression levels of NRF2, PCNA, and LC3B. Data are representative of at least 3 independent 
experiments.  
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Discussion 
 This study aimed to better understand autophagy inhibition’s in vitro effects on Wnt 
driven, claudin-low Triple negative breast cancer and to determine if autophagy inhibition in 
combination with nutrient or chemotherapeutic stress is a viable therapy to be tried in vivo 
murine models. The study produced evidence displaying autophagy inhibition’s widespread 
effects on cellular behavior and identified two specific stressors, serum starvation and 
Doxorubicin, that work synergistically with autophagy inhibition. Mechanisms behind 
Doxorubicin’s effect appear to be reactive oxygen species related, however a mechanism for 
serum starvation’s effect was not directly identified.  
 Autophagy deficiency alone in both the M-Wnt and metM-Wntlung cell lines resulted in 
moderate reduction in growth and colony formation over time, consistent with the weak effects 
of unaccompanied autophagy inhibition in the literature56,57. Even under nutrient replete 
conditions, it appears that autophagy deficiency causes accumulations of damaged mitochondria 
within the cancer cells. Decreased mitochondrial membrane polarization, reduced mitochondrial 
superoxide (a normal by-product of oxidative phosphorylation), and lowered maximum oxygen 
consumption rate all signal impairments in mitochondrial oxidative phosphorylation. Mitophagy, 
a selective method for mitochondrial degradation by autophagy, is not affected by ATG5 
knockout, but appears to have a negligible effect on clearing damaged mitochondria in this case.  
On a cellular scale, damaged mitochondria impair energy generation and biosynthesis, but on a 
large tumor scale, accumulation of damaged mitochondria and autophagy deficiency are 
associated with benign oncocytomas rather than carcinomas in their autophagy competent 
counterparts58. Additionally, autophagy inhibition appeared to marginally induce EMT reversion, 
as seen by the downregulation of mesenchymal EMT transcription factors and a shift towards E-
Cadherin over N-Cadherin, recognized markers of a mesenchymal to epithelial transition (MET) 
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21,49,52. While it is unclear whether EMT is dependent on autophagy or if EMT and autophagy act 
in parallel to promote invasive phenotypes, TGF-β signaling may drive autophagy inhibition’s 
induction of an MET. Autophagy inhibition attenuates TGF-β signaling, and in one study 
hepatocellular carninomas required autophagy for TGF-β signaling59,60. TGF-β signaling induces 
EMT, and thus if TGF-β signaling in a steady state is decreased, EMT correspondingly 
reverses59,60.   
 1% FBS media, in contrast to the 10% FBS media cells are usually cultured in, acts 
synergistically with autophagy inhibition to decrease growth. 1% FBS is additionally considered 
one of the best methods to mimic calorie restriction in vitro, as FBS contains amino acids, lipids, 
hormones, growth factors, and cytokines, it provides a more realistic systemic nutrient 
deprivation effect than restricting a singular nutrient37,62. The mechanism for 1% FBS’s effects 
may not lie within the mTOR pathway that calorie restriction is believed to act through, as 
treatments with Metformin, an AMPK activator/mTOR inhibitor, and BMS-754807 had no 
combined effect with autophagy inhibition. However, AKT dependent, mTOR independent 
effects downstream of PI3K could be responsible for ATG5 knockout sensitization to 1% FBS. 
The PI3K/AKT pathway integrates multiple nutrient status, growth factor, and stress signals, all 
of which would be altered by 1% FBS 
 
Of the chemotherapeutic agents assayed in combination with autophagy inhibition, 
Doxorubicin was the only agent to decrease survival synergistically with autophagy inhibition. 
Doxorubicin is also the only agent known to produce free radicals in addition to its primary 
cytotoxic mechanism as a DNA intercalating agent63,64. An inability of autophagy deficient cells 
to properly respond to increased ROS as a result of Doxorubicin induced free radicals may 
explain its unique effectiveness in these cells. Reactive oxygen species are a major regulator of 
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autophagy, and evidence shows that autophagy acts similar to a negative feedback loop where 
ROS-induced autophagy brings oxidative stress levels back down to a healthy level by removing 
damaged organelles17. In autophagy deficient cells, ROS cannot be brought back down as easily, 
and additional ROS formed as a result of Doxorubicin treatment induce apoptosis. This 
explanation tracks well with the general ROS flow cytometry data; despite basally having lower 
reactive oxygen species than the Wild-Type, the ATG5 knockouts have much higher ROS than 
the Wild-Type with Doxorubicin treatment, but not Gemcitabine treatment. Furthermore, the 
lower basal ROS in the ATG5 knockouts can be explained by NRF2 induction. Autophagy 
substrate p62 is upregulated with cellular stress and has the role of inducing autophagy under 
basal conditions. P62 also interacts with Keap1, a ubiquitin ligase involved in degrading NRF2, 
and competes for the NRF2 binding site, thus releasing NRF2 in p62 presence. Autophagy 
deficient cells cannot clear p62 and accumulate it, resulting in stabilized NRF2 and high 
transcriptional antioxidant activity65,66. With added exogenous stress however, p62 may be 
induced and accumulate at toxic levels, inducing additional oxidative and electrophilic stress in 
both NRF2 dependent and independent manners65,66. In short, autophagy deficient cells may have 
a decreased ability to respond to the additional oxidative stress of Doxorubicin treatment due to 
p62 accumulation without increased NRF2 antioxidant activity.  
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Conclusions 
We conclude that autophagy inhibition combination therapy in Wnt driven, claudin-low 
Triple negative breast cancer does represent a strong potential avenue for adjuvant and 
neoadjuvant therapies with the addition of nutrient or chemotherapeutic stress. However, specific 
molecular targets that work in accord with autophagy must be identified if therapies are to be 
brought to practical levels of efficacy. 
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